ARIES-HM3 TRIAL

ASPIRIN-FREE WITH HEARTMATE 3™ LVAD

The ARIES-HM3 trial showed that the avoidance of aspirin can have positive results for HeartMate 3™ LVAD patients by reducing bleeding events.[1]*

Because of this compelling data, the FDA has approved an update to the HeartMate 3 LVAD IFU to remove aspirin from the required anticoagulation regimen. Find out why and visit us at booth 439.

THE FIRST AND ONLY INTERNATIONAL RANDOMIZED CONTROLLED TRIAL

to study the effects of aspirin avoidance on LVAD patients[1]

SIGNIFICANT REDUCTION IN RISK OF BLEEDING EVENTS

Nearly 40% reduction in GI bleeding events[1]

Reduction of risk in nonsurgical bleeding events[1]

THE AVOIDANCE OF ASPIRIN WAS PROVEN SAFE:

NO INCREASE in thrombosis[1]

NO INCREASE in stroke risk[1]

Reduction in hospitalization days due to bleeding events[1]**



Reduction in cost of care for bleeding events[1]**

FOR MORE INFORMATION, VISIT US AT BOOTH 439.

CONTINUED IMPROVEMENTS IN PATIENT OUTCOMES

Reduced bleeding events in the ARIES-HM3 trial are similar in magnitude to the reduction of bleeding events that was achieved with the introduction of the HeartMate 3™ LVAD.[1,2]

MOMENTUM 3 TRIAL[2]

Improvement with the HeartMate 3 LVAD

GI bleeding events per 100 patient-years



ARIES-HM3 TRIAL[1]

Further improvement with the avoidance of aspirin

GI bleeding events per 100 patient-years



For patients with advanced heart failure, the HeartMate 3 LVAD is a proven long-term, life-extending therapy.[2] By avoiding aspirin,* outstanding outcomes are made even better.[1]

GI = gastrointestinal
IFU = Instructions for Use
LVAD = left ventricular assist device

*Newly implanted HeartMate 3™ LVAD adult patients. ARIES-HM3 trial studied patients only 18 and over. Decisions regarding the pharmacological management of HeartMate 3 LVAD patients should be individualized by clinicians after fully considering potential risks and benefits.
**Based on U.S. patients only.

1. Mehra MR, Netuka I, Uriel N, et al. Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure: the ARIES-HM3 randomized clinical trial. *JAMA*. 2023;330(22):2171-2181. doi:10.1001/jama.2023.23204

2. Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. *JAMA*. 2022;328(12):1233-1242. doi:10.1001/jama.2022.16197

Abbott
6101 Stoneridge Dr., Pleasanton, CA 94588 USA, Tel: 1 925 847 8600
Cardiovascular.Abbott/HeartMate

Rx Only
Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

HeartMate 3™ LVAS Indications: The HeartMate 3™ Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

HeartMate II™ LVAS Indications: The HeartMate II™ Left Ventricular Assist System is indicated for use as a "bridge to transplantation" for cardiac transplant candidates who are at risk of imminent death from non-reversible left ventricle failure. It is also indicated for use in patients with New York Heart Association (NYHA) Class IIIB or IV end-stage left ventricular failure, who have received optimal medical therapy for at least 45 of the last 60 days, and who are not candidates for cardiac transplantation. The HeartMate II Left Ventricular Assist System is intended for use both inside and outside of the hospital, or for transportation of Left Ventricular Assist Device patients via ground ambulance, airplane, or helicopter.

HeartMate 3™ and HeartMate II™ LVAS Contraindications: The HeartMate 3 and HeartMate II Left Ventricular Assist Systems are contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

HeartMate 3™ and HeartMate II™ LVAS Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 or HeartMate II Left Ventricular Assist System are listed below: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) and possible pump thrombosis.

MAT-2408972 v1.0 | Item approved for U.S. use only.

Abbott